What is the purpose and procedure of the desmopressin (DDAVP) challenge test in diagnosing central diabetes insipidus (DI) versus nephrogenic diabetes insipidus (NDI)?

Desmopressin Challenge Test for Differentiating Central vs. Nephrogenic Diabetes Insipidus

The desmopressin (DDAVP) challenge test is the gold standard diagnostic procedure for differentiating central diabetes insipidus (DI) from nephrogenic DI, with a significant increase in urine osmolality after desmopressin administration indicating central DI, while minimal or no response indicates nephrogenic DI. 1

Purpose of the Desmopressin Challenge Test

The primary purposes of this test are:

• To distinguish between central DI (deficiency of antidiuretic hormone/ADH) and nephrogenic DI (kidney resistance to ADH)
• To differentiate both forms of DI from primary polydipsia
• To determine the appropriate treatment approach, as desmopressin is effective for central DI but ineffective for nephrogenic DI 2, 3

Diagnostic Criteria

The following table summarizes the diagnostic criteria for different polyuric conditions:

Condition	Urine Osmolality	Serum Sodium	Response to Desmopressin
Central DI	<200 mOsm/kg	>145 mmol/L	Significant increase
Nephrogenic DI	<200 mOsm/kg	>145 mmol/L	Minimal/no increase
Primary Polydipsia	Variable, can exceed 300 mOsm/kg after water deprivation	Normal or low	Minimal increase
Partial DI	250-750 mOsm/kg	Variable	Partial increase

1

Procedure for Desmopressin Challenge Test

1. Water Deprivation Phase:

   • Withhold fluids for a specified period (typically 8-12 hours)
   • Monitor body weight, urine output, urine osmolality, and serum sodium
   • Continue until urine osmolality stabilizes (two consecutive measurements with <30 mOsm/kg difference) or clinical safety limits are reached

2. Desmopressin Administration:

   • Administer desmopressin (typically 2-4 μg IV/SC or 10-40 μg intranasally) 4
   • Continue to monitor urine osmolality for several hours after administration

3. Interpretation of Results:

   • Central DI: Significant increase in urine osmolality (>50% from baseline)
   • Nephrogenic DI: Minimal or no increase in urine osmolality (<10% from baseline)
   • Partial central DI: Intermediate response (10-50% increase)

Modern Diagnostic Approaches

While the desmopressin challenge test remains valuable, newer approaches are emerging:

• Plasma copeptin measurement: Copeptin (released in equimolar ratio with AVP) levels >21.4 pmol/l in adults are diagnostic for nephrogenic DI, potentially avoiding the need for challenge testing 5

• Genetic testing: Strongly recommended, especially in congenital cases, using massively parallel sequencing-based multigene panels that include at least AQP2, AVPR2, and AVP genes 5

Clinical Considerations and Pitfalls

• Safety concerns: Water deprivation can cause dangerous dehydration in patients with severe DI; close monitoring is essential

• False results: Medications, kidney disease, and other conditions can affect test results

• Partial responses: Some patients with partial forms of DI may show intermediate responses that are difficult to interpret

• Alternative delivery routes: When nasal administration is compromised (nasal congestion, discharge, atrophy, etc.), parenteral administration may be necessary 2, 3

• Rare cases: Some cases of nephrogenic DI may show partial response to supraphysiologic doses of desmopressin, though this is uncommon 6

Treatment Implications

The test results directly guide treatment:

• Central DI: Desmopressin is the treatment of choice 2, 4

• Nephrogenic DI: Desmopressin is ineffective; treatment includes thiazide diuretics, amiloride, NSAIDs, and ensuring adequate fluid intake 1, 7

The desmopressin challenge test remains a cornerstone diagnostic procedure in the evaluation of polyuric disorders, providing crucial information that guides appropriate treatment selection and management strategies.